Met Life Investment Management, LLC Hille Vax, Inc. Transaction History

Met Life Investment Management, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$11.86 - $15.93 $32,294 - $43,377	2,723 Added 18.92%	17,118 $247,000
Q1 2024 May 14, 2024	BUY	$14.15 - $19.75 $203,689 - $284,301	14,395 New	14,395 $239,000
Q4 2023 Feb 14, 2024	BUY	$10.35 - $17.11 $29,290 - $48,421	2,830 Added 24.47%	14,395 $231,000
Q3 2023 May 09, 2024	BUY	$11.59 - $16.7 $33,147 - $47,762	2,860 Added 32.85%	11,565 $155,000
Q2 2023 Apr 29, 2024	BUY	$12.93 - $18.76 $149,535 - $216,959	11,565 New	11,565 $198,000
Q2 2023 Aug 10, 2023	BUY	$12.93 - $18.76 $36,979 - $53,653	2,860 Added 32.85%	11,565 $198,000
Q1 2023 May 09, 2024	BUY	$14.73 - $18.18 $128,224 - $158,256	8,705 New	8,705 $144 Million
Q1 2023 May 15, 2023	BUY	$14.73 - $18.18 $9,824 - $12,126	667 Added 8.3%	8,705 $143,000
Q4 2022 Jun 14, 2023	SELL	$13.52 - $21.46 $9,017 - $14,313	-667 Reduced 7.66%	8,038 $134,000
Q3 2022 May 10, 2024	BUY	$10.5 - $22.01 $84,399 - $176,916	8,038 New	8,038 $137,000
Q3 2022 Jun 14, 2023	SELL	$10.5 - $22.01 $7,003 - $14,680	-667 Reduced 7.66%	8,038 $137,000
Q3 2022 Nov 14, 2022	BUY	$10.5 - $22.01 $84,399 - $176,916	8,038 New	8,038 $137,000

36.8M

Ticker HLVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,427,200
Market Cap $65.5M
Description
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Met Life Investment Management, LLC with notifications on news.